Keyphrases
Neuromyelitis Optica
100%
Aquaporin-4 (AQP4)
100%
High-income Countries
100%
Treatment Access
100%
Low-income Countries
75%
Myelin Oligodendrocyte Glycoprotein Antibody
75%
Diagnostic Test
50%
Antibody Test
50%
University-based
25%
Response Rate
25%
Rituximab
25%
Am(III)
25%
Methylprednisolone
25%
Immunosuppressive Therapy
25%
Geographic Region
25%
World Bank
25%
Mycophenolate Mofetil
25%
Neurologist
25%
Intravenous Immunoglobulin (IVIg)
25%
Acute Treatment
25%
World Regions
25%
Diagnostic Interventions
25%
Spanish-English Bilinguals
25%
Oral Prednisone
25%
Public Assistance
25%
Plasma Exchange
25%
Country Income Level
25%
Income Groups
25%
Structured Survey
25%
Catastrophic Health Expenditure
25%
Eastern Mediterranean Countries
25%
Medicine and Dentistry
Neuromyelitis Optica
100%
Aquaporin 4 Antibody
100%
Myelin Oligodendrocyte Glycoprotein
75%
Diagnosis
50%
Health Care Cost
50%
Methylprednisolone
25%
Immunosuppressive Treatment
25%
Immunoassay
25%
Prednisone
25%
Rituximab
25%
Azathioprine
25%
Immunoglobulin
25%
Health Expenditure
25%
Plasma Exchange
25%
Mycophenolic Acid
25%
Immunology and Microbiology
Neuromyelitis Optica
100%
Aquaporin 4 Antibody
100%
Myelin Oligodendrocyte Glycoprotein
75%
Methylprednisolone
25%
Intravenous Immunoglobulin
25%
Blood Plasma
25%
Prednisone
25%
Immunosuppressive Drug
25%
Azathioprine
25%
Rituximab
25%
Mycophenolic Acid
25%
Neuroscience
Neuromyelitis Optica
100%
Aquaporin 4 Antibody
100%
Myelin Oligodendrocyte Glycoprotein
75%
Rituximab
25%
Intravenous Immunoglobulin
25%
Methylprednisolone
25%
Immunosuppressive Drug
25%
Prednisone
25%
Azathioprine
25%
Mycophenolate Mofetil
25%